VR Logo

Inventiva S.A. (IVA) download report


Healthcare | Biotechnology & Pharma Research

Inventiva S.A. (IVA) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases.

IPO Date: 10-Jul-2020

Co-Founder, CEO & Chairman: Mr. Frederic Cren

Co-Founder, Chief Scientific Officer, Deputy CEO & Director: Dr. Pierre Broqua Ph.D.

Listing: NASDAQ: IVA

Country: France

Headquarters: Daix,

Website: https://www.inventivapharma.com

Key Facts

Market cap: $289.05 Mln

Revenue (TTM): $0.14 Mln

Earnings (TTM): $-49.64 Mln

Cash: $0.00 Mln

Total Debt: $0.00 Mln

Insider's Holding: 0.00%

Liquidity: Low

52 Week range: $6.29 - 15.78

Shares outstanding: 40,873,600

9 Years Aggregate:

  • CFO: $-217.47 Mln
  • EBITDA: $-212.07 Mln
  • Net Profit: $-194.81 Mln

Stock Performance

Time Period Inventiva S.A. (IVA) S&P BSE Sensex S&P Small-Cap 600
YTD-51.83-8.74-17.05
1 month-28.32-2.01-4.75
3 months-40.72-7.32-12.65
1 Year-51.970.45-16.28
3 Years--10.328.01
5 Years--11.296.35
10 Years--12.1410.55
As on 27-Jun-2022
Year Inventiva S.A. (IVA) S&P Small-Cap 600 S&P BSE Sensex
2021-5.7925.2721.99